Research On Earnings Quality Of Changchungaoxin Company

With the rapid development of China's economy and the aggravation of the ageing population,the living standard of the people is improving while the pace of life is speeding up and the pressure of social work is increasing.Therefore,the Chinese people are attaching more and more importance to health problems.The pharmaceutical industry,which is closely related to our health and living quality,is highly regarded by the world.Many countries in the world regard biopharmaceutical industry as a high-tech strategic industry with priority development.In recent years,China has continuously formulated favorable policies to increase national support.Biopharmaceutical industry has become one of the most promising industries in the world,which also brings huge development space to Chinese companies.But biopharmaceutical industry in China started late.For this kind of high costs,long cycle and big risk industry,there is still a big gap between China and other developed countries.Chinese companies' market competitiveness is weak,and some companies resort to fraud for immediate benefits,which not only disturbs the industry,but also causes harm to people's health.In addition,with high investment and high failure rate in this industry,companies are easy to get into operational difficulties.Only those companies with independent core technologies and excellent management capabilities are likely to succeed in the future.Therefore,it is of practical significance to choose biopharmaceutical companies to research on company earnings quality.It can bring reference to the healthy development of Chinese companies and improve their competitiveness in the world market.At the same time,it also provides an evaluation method for the users of relevant information in the capital market.Changchungaoxin is a leading company in the biopharmaceutical industry in China,with several leading vaccine products.Its subsidiary corporation,Jinsaiyaoye,is the national demonstration base for the quality of genetically engineered drugs.Changchungaoxin company will be a representative biopharmaceutical company in China in the future,so more attention should be paid to it.Based on the research results of earning quality at hom e and abroad,this paper makes further systematic induction and summary.Firstly,the difference between earning ability and earning quality is made clear.The quality of earnings is more reliable in judging the state of business.Then,according to the characteristics and influencing factors of the company's earning quality,this paper selects several judgment indexes to form a more comprehensive evaluation system of the company's earning quality.Based on the data provided by the financial reports of Changchungaoxin?Yunnanbaiyao and Zhifeishengwu from 2014—2018,the indicators in the system are explained and analyzed.Judging from the obtained data that there are some problems in the ea rning quality of Changchungaoxin company,this paper analyzes the causes of the problem and puts forward the solutions.The method of earning quality evaluation put forward in this paper is scientific and effective,and it pays more attention to practical operability and universal applicability.The index is easy to understand and the data is easy to obtain.The conclusion can reflect the actual problem and can provide the reference for other companies to analyze the earning quality.